Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Eye Care, PA

Neither a doctor nor a teaching hospital

Research payments

$2,855,088

131 payments

Through program year 2025, Total Eye Care, PA is reported as receiving $2,855,088 in research payments, across 131 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $604,168 14
2024 Research $400,684 13
2023 Research $376,638 31
2022 Research $789,038 41
2021 Research $569,432 22
2019 Research $115,127 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ocular Therapeutix, Inc. $867,632 19 payments
  2. Bausch & Lomb Americas Inc. $685,906 39 payments
  3. Glaukos Corporation $468,897 28 payments
  4. Oyster Point Pharma, Inc. $359,400 11 payments
  5. Alcon Research LLC $182,031 14 payments
  6. Padagis US LLC $141,350 4 payments
  7. Perrigo Company plc $94,150 5 payments
  8. Aerie Pharmaceuticals, Inc. $53,660 5 payments
  9. Novartis Pharmaceuticals Corporation $1,985 4 payments
  10. Johnson & Johnson Vision Care, Inc. $76 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (LYNX-2) $283,144 7 payments
  2. A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED) $273,760 8 payments
  3. OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) $259,141 1 payment
  4. A Randomized, Multicenter, Double-Masked, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness $244,768 3 payments
  5. A Randomized, Multi-center, Double-masked, Vehicle-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI (Cyclosporine Ophthalmic Insert) for Intracanalicular Use for the Treatment of Subjects With Dry Eye Disease (DED) $217,305 7 payments
  6. Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $141,350 4 payments
  7. A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled Evaluation of the Onset and Duration of Action of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model $125,690 6 payments
  8. Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle Glaucoma or Ocular Hypertension $119,900 8 payments
  9. A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy $114,079 6 payments
  10. A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled Evaluation of the Onset and Duration of Action of the Combination Drug Product Brimonidine Tartrate 0.025% / Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to its Components and Vehicle in an Allergen BioCube (ABC) Clinical Trial in Subjects with Seasonal Allergic Conjunctivitis $101,301 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record